Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
Bairavi Shankar(Bloomberg (United States)), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), David S. Ettinger(Johns Hopkins University), Biagio Ricciuti(Harvard University), Paul R. Walker(East Carolina University), Kristen A. Marrone(Johns Hopkins University), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Christine L. Hann(Johns Hopkins University), Josephine Feliciano(Sidney Kimmel Comprehensive Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Abdul Rafeh Naqash(Oklahoma City University), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Yukihiro Toi(Sendai Kousei Hospital), Jiajia Zhang(Bloomberg (United States)), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sandip H. Patel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Julie R. Brahmer(Johns Hopkins University)
Cited by 498
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k